Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia

Abstract

Twenty-five patients with hypercalcaemia (ionised calcium, 1.57 ± 0.04 mM; total calcium, 3.33 ± 0.06 mM) due to malignancy were randomised to receive pamidronate (1 mg/kg body wt.) by infusion over 4 h (12 patients) or 24 h (13 patients). Forced saline diuresis was not utilised. Two patients died within 24 h and were not included in the analysis. Both groups combined ( n = 23) showed a decrease in ionised calcium to 1.44 ± 0.04 mM by 2 days ( P < 0.05 vs. day 0). By 4 days there had been a further fall to 1.27 ±0.05 mM ( P < 0.05 vs. day 2) and 7 days after treatment ionised calcium was 1.19 ± 0.05 mM ( P < 0.05 vs. day 4). Total calcium declined from 3.33 ± 0.06 to 2.65 ± 0.11 mM over 7 days ( P < 0.001). Separate analyses of the two groups showed that the fast (4-h) infusion led to an earlier reduction in calcium than did the 24-h infusion ( P < 0.02), although after 7 days there was little difference between the two groups (4 h, 1.18 ± 0.09 mM; 24 h, 1.23 ± 0.06 mM, n.s.). Hypercalcaemic symptoms (analogue rating scale) improved between each of the time intervals 0,4 and 7 days ( P < 0.05) and did not differ between the two groups. We recommend a single 4-h infusion of pamidronate (1 mg/kg) as primary treatment for malignancy-induced hypercalcaemia.